Addiction is yet another area where GLP-1s might be effective. Preliminary evidence looks promising, but questions remain.
Some of what RFK Jr. says about obesity prevention isn't new. But after having coined the catchy MAHA acronym, it’s likely ...
Obese people ‘will have to wait’ for Mounjaro amid carefully managed NHS rollout - The decision will help ‘protect other ...
There’s no single GLP-1 diet plan you need to follow. If you’re taking — or thinking about taking — a GLP-1 medication like ...
Amid the war on obesity, a clear winner has emerged in a battle between two weight-loss injectables. Zepbound (tirzepatide), ...
A cross-sectional study of privately insured patients with obesity showed that the use of GLP-1 RAs soared from 2022 to 2023, ...
The table below is a review of notable updates that occurred in November 2024 for investigational products in development (not an inclusive list). Click on the status to view our full coverage. The ...
However, Dr Kath McCullough, NHS England’s national speciality adviser for obesity, warned that weight loss jabs “are not a ...
Pharmaceutical giants Eli Lilly and Company & Novo Nordisk A/S face challenges in the obesity market despite promising data.
A study finds that anti-obesity medications may help reduce alcohol consumption, with nearly half of participants in weight ...
Other work primarily only included glucagon-like peptide-1 receptor agonists (GLP-1 RAs) among individuals with substance use disorders. We also compared GLP-1 RAs to metformin and ...
Patients lost an average of 20.2% of their weight with tirzepatide over 72 weeks versus 13.7% with semaglutide.